推进帕金森病的个性化医疗:改变治疗和治疗结果
M Swathi1, Sai Sankeerthana Bedadakota1, Andhere Animish1
1Department of Biomedical Sciences School of Biosciences and Technology , Vellore Institute of Technology , Vellore, Tamil Nadu 632014 India.
3 Biotech
|March 12, 2026
概括
个性化医疗为帕金森病 (PD) 提供量身定制的治疗方法,超越一刀切的方法. 这种转变利用遗传和生物标志物数据来改善诊断,预测进展,并个性化治疗,以获得更好的神经退行性疾病管理结果.
科学领域:
- 神经学 神经学
- 遗传学 是一个遗传学.
- 个性化医疗是个性化的医疗.
背景情况:
- 像帕金森病 (PD) 这样的神经退行性疾病由于多因素原因和多种症状而带来复杂的挑战.
- 目前的PD治疗方法,包括利沃多巴和深度大脑刺激,显示出可变的疗效,突出显示出需要个性化治疗策略.
- 患病症的异质性需要从通用治疗转向个性化医疗方法.
研究的目的:
- 审查个性化医疗在帕金森病管理中的必要性和进展.
- 分析个人化PD护理当前的技术,局限性和创新技术.
- 为了全面了解个性化医疗如何改变帕金森病的治疗.
主要方法:
- 关于帕金森病个性化医学的文献综述.
- 对遗传,生物标志物和表型数据应用的分析.
- 评估针对个性化治疗的创新技术和策略.
主要成果:
- 个性化医疗提高了帕金森病的诊断准确度和疾病进展预测.
- 基于患者特定数据的个性化治疗方案提供了更好的治疗结果.
- 基因和生物标记信息是为帕金森病患者量身定制干预措施的关键.
结论:
- 个性化医疗代表了帕金森病管理的范式转变,朝着量身定制的患者护理迈进.
- 整合遗传,生物标志物和表型数据对于优化帕金森病的诊断和治疗至关重要.
- 进一步的研究和技术整合至关重要,以充分实现个性化医学的潜力,打击像帕金森氏症这样的神经退行性疾病.
相关概念视频
Parkinson's Disease: Treatment
1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
Parkinson's Disease: Overview
2.3K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.3K
Combination Therapies and Personalized Medicine
6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Combination Therapies and Personalized Medicine
1.7K
1.7K
EPS and iPS Cells in Disease Research
3.5K
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
3.5K
Pharmacogenomics: Identification of New Drug Targets
61
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
61


